Case characterization, clinical features and risk factors in drug-induced liver injury

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Ortega Alonso, Aida ^a   Stephens, Camilla ^a,b   Lucena, M Isabel ^a,b   Andrade, Raúl J ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

DILI; Drug induced liver injury; Risk factors

Indexed keywords

ACARBOSE; ALBENDAZOLE; ALKALINE PHOSPHATASE; ALLOPURINOL; AMFEBUTAMONE; AMIODARONE; AMITRIPTYLINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ATORVASTATIN; BILIRUBIN; CAPTOPRIL; CARBAMAZEPINE; CELECOXIB; CHLORPROMAZINE; CHLORPROPAMIDE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOPIDOGREL; CLOXACILLIN; DIAZEPAM; DICLOXACILLIN; DISULFIRAM; ENALAPRIL; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 10; PARACETAMOL; UNINDEXED DRUG;

ACUTE LIVER FAILURE; AGE; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; GENDER; GENETIC ASSOCIATION; HUMAN; JAUNDICE; LIPOPHILICITY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RACE; REVIEW; RISK FACTOR; TOXIC HEPATITIS; VEIN OCCLUSION; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; MALE;

CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HUMANS; MALE;

EID: 84967106756     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050714     Document Type: Review

References (108)

1. Andrade, R.J.; Lucena, M.I.; Kaplowitz, N.; García-Muñoz, B.; Borraz, Y.; Pachkoria, K.; García-Cortés, M.; Fernández, M.C.; Pelaez, G.; Rodrigo, L., et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44, 1581–1588. [CrossRef] [PubMed]
2. Andrade, R.J.; Lucena, M.I.; Fernández, M.C.; Pelaez, G.; Pachkoria, K.; García-Ruiz, E.; García-Muñoz, B.; González-Grande, R.; Pizarro, A.; Durán, J.A., et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129, 512–521. [CrossRef] [PubMed]
3. Navarro, V.J.; Seeff, L.B. Liver injury induced by herbal complementary and alternative medicine. Clin. Liver Dis. 2013, 17, 715–735. [CrossRef] [PubMed]
4. Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002, 36, 451–455. [CrossRef] [PubMed]
5. Bjornsson, E.S.; Bergmann, O.M.; Bjornsson, H.K.; Kvaran, R.B.; Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144, 1419–1425. [CrossRef] [PubMed]
6. Chalasani, N.; Bonkovsky, H.L.; Fontana, R.; Lee, W.; Stolz, A.; Talwalkar, J.; Reddy, K.R.; Watkins, P.B.; Navarro, V.; Barnhart, H., et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015, 148, 1340–1352. [CrossRef] [PubMed]
7. Suk, K.T.; Kim, D.J.; Kim, C.H.; Park, S.H.; Yoon, J.H.; Kim, Y.S.; Baik, G.H.; Kim, J.B.; Kweon, Y.O.; Kim, B.I., et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012, 107, 1380–1387. [PubMed]
8. Andrade, R.J.; López-Ortega, S.; López-Vega, M.C.; Robles, M.; Cueto, I.; Lucena, M.I. Idiosyncratic drug hepatotoxicity: A 2008 update. Expert Rev. Clin. Pharmacol. 2008, 1, 261–276. [CrossRef] [PubMed]
9. Ostapowicz, G.; Fontana, R.J.; Schiødt, F.V.; Larson, A.; Davern, T.J.; Han, S.H.; McCashland, T.M.; Shakil, A.O.; Hay, H.E.; Hynan, L., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002, 137, 947–954. [CrossRef] [PubMed]
10. Reuben, A.; Koch, D.G.; Lee, W.M. Group ALFS. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 2010, 52, 2065–2076. [CrossRef] [PubMed]
11. Hayashi, P.H.; Fontana, R.J. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin. Liver Dis. 2014, 34, 134–144. [PubMed]
12. Aithal, G.P.; Watkins, P.B.; Andrade, R.J.; Larrey, D.; Molokhia, M.; Takikawa, H.; Hunt, C.M.; Wilke, R.A.; Avigan, M.; Kaplowitz, N., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011, 89, 806–815. [CrossRef] [PubMed]
13. Robles-Diaz, M.; Garcia-Cortes, M.; Medina-Caliz, I.; González-Jiménez, A.; González-Grande, R.; Navarro, J.M.; Castiella, A.; Zapata, E.M.; Romero-Gómez, M.; Blanco, S., et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int. 2015, 35, 2474–2482. [CrossRef] [PubMed]
14. Robles-Diaz, M.; Lucena, M.I.; Kaplowitz, N.; Stephens, C.; Medina-Cáliz, I.; González-Jiménez, A.; Ulzurrun, E.; González, A.F.; Fernández, M.C.; Romero-Gómez, M., et al. Use of Hy’s Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology 2014, 147, 109–118. [CrossRef] [PubMed]
15. Kleiner, D.E.; Chalasani, N.P.; Lee, W.M.; Fontana, R.J.; Bonkovsky, H.L.; Watkins, P.B.; Hayashi, P.H.; Davern, T.J.; Navarro, V.; Reddy, R., et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology 2014, 59, 661–670. [CrossRef] [PubMed]
16. Fontana, R.J.; Watkins, P.B.; Bonkovsky, H.L.; Chalasani, N.; Davern, T.; Serrano, J.; Rochon, J.; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 2009, 32, 55–68. [CrossRef] [PubMed]
17. Zimmerman, H.J. The spectrum of hepatotoxicity. Perspect. Biol. Med. 1968, 12, 135–161. [CrossRef] [PubMed]
18. FDA. Draft Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Available online: https://www.federalregister.gov/articles/2009/07/30/E9-18135/guidance-for-industry-on-druginduced-liver-injury-premarketing-clinical-evaluation-availability (accessed on 16 February 2016).
19. Pachkoria, K.; Lucena, M.I.; Crespo, E.; Ruiz-Cabello, F.; López-Ortega, S.; Fernández, M.A.; Romero-Gómez, M.; Madrazo, A.; Durán, J.A.; de Dios, A.M., et al. Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome. J. Hepatol. 2008, 49, 107–114. [CrossRef] [PubMed]
20. Andrade, R.J.; Robles, M.; Fernández-Castañer, A.; López-Ortega, S.; López-Vega, M.C.; Lucena, M.I. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J. Gastroenterol. 2007, 13, 329–340. [CrossRef] [PubMed]
21. Zimmerman, H.J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed.; LippincottWilliams & Wilkins: Philadelphia, PA, USA, 1999.
22. Fisher, K.; Vuppalanchi, R.; Saxena, R. Drug-Induced Liver Injury. Arch. Pathol. Lab. Med. 2015, 139, 876–887. [CrossRef] [PubMed]
23. Ramachandran, R.; Kakar, S. Histological patterns in drug-induced liver disease. J. Clin. Pathol. 2009, 62, 481–492. [CrossRef] [PubMed]
24. Fontana, R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014, 146, 914–928. [CrossRef] [PubMed]
25. Goodman, Z.D. Drug hepatotoxicity. Clin. Liver Dis. 2002, 6, 381–397. [CrossRef]
26. Larrey, D. Drug-induced liver diseases. J. Hepatol. 2000, 32, 77–88. [CrossRef]
27. Lucena, M.I.; Andrade, R.J.; Kaplowitz, N.; García-Cortés, M.; Fernández, M.C.; Romero-Gómez, M.; Bruguera, M.; Hallal, H.; Robles-Díaz, M.; Rodríguez-González, J.F., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology 2009, 49, 2001–2009. [CrossRef] [PubMed]
28. Robles-Diaz, M.; Gonzalez-Jimenez, A.; Medina-Caliz, I.; Stephens, C.; García-Cortés, M.; García-Muñoz, B.; Ortega-Alonso, A.; Blanco-Reina, E.; González-Grande, R.; Jiménez-Pérez, M., et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment. Pharmacol. Ther. 2015, 41, 116–125. [CrossRef] [PubMed]
29. Martinez, M.A.; Vuppalanchi, R.; Fontana, R.J.; Stolz, A.; Kleiner, D.E.; Hayashi, P.H.; Gu, J.; Hoofnagle, J.H.; Chalasani, N. Clinical and histologic features of azithromycin-induced liver injury. Clin. Gastroenterol. Hepatol. 2015, 13, 369–376. [CrossRef] [PubMed]
30. Orman, E.S.; Conjeevaram, H.S.; Vuppalanchi, R.; Freston, J.W.; Rochon, J.; Kleiner, D.E.; Hayashi, P.H.; DILIN Research Group. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin. Gastroenterol. Hepatol. 2011, 9, 517–523. [CrossRef] [PubMed]
31. Bjornsson, E.S.; Jonasson, J.G. Drug-induced cholestasis. Clin. Liver Dis. 2013, 17, 191–209. [CrossRef] [PubMed]
32. Benichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990, 11, 272–276. [PubMed]
33. Medina-Cáliz, I.; Robles-Díaz, M.; García-Muñoz, B.; Stephens, C.; Ortega-Alonso, A.; García-Cortés, M.; González-Jiménez, A.; Sanabria-Cabrera, J.; Moreno, I.; Fernández, C., et al. Definition, incidence and risk factors for chronicity following acute idiosyncratic drug-induced licer injury. J. Hepatol. 2016. in press.
34. Delemos, A.S.; Foureau, D.M.; Jacobs, C.; Ahrens, W.; Russo, M.W.; Bonkovsky, H.L. Drug-induced liver injury with autoimmune features. Semin. Liver Dis. 2014, 34, 194–204. [PubMed]
35. Castiella, A.; Zapata, E.; Lucena, M.I.; Andrade, R.J. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J. Hepatol. 2014, 6, 160–168. [CrossRef] [PubMed]
36. Danan, G.; Teschke, R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int. J. Mol. Sci. 2015, 17. [CrossRef] [PubMed]
37. Bjornsson, E.; Talwalkar, J.; Treeprasertsuk, S.; Kamath, P.S.; Takahashi, N.; Sanderson, S.; Neuhauser, M.; Lindor, K. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology 2010, 51, 2040–2048. [CrossRef] [PubMed]
38. Foureau, D.M.; Walling, T.L.; Maddukuri, V.; Anderson, W.; Cullbreath, K.; Kleiner, D.E.; Ahrens, W.A.; Jacobs, C.; Watkins, P.B.; Chalasani, N., et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin. Exp. Immunol. 2015, 180, 40–51. [CrossRef] [PubMed]
39. Rodrigues, S.; Lopes, S.; Magro, F.; Cardoso, H.; Horta e Vale, A.M.; Marques, M.; Mariz, E.; Bernardes, M.; Lopes, J.; Carneiro, F., et al. Autoimmune hepatitis and anti-tumor necrosis factor α therapy: A single center report of 8 cases. World J. Gastroenterol. 2015, 21, 7584–7588. [CrossRef] [PubMed]
40. Perdices, E.V.; Medina-Cáliz, I.; Hernando, S.; Ortega, A.; Martín-Ocaña, F.; Navarro, J.M.; Peláez, G.; Castiella, A.; Hallal, H.; Romero-Gómez, M., et al. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev. Esp. Enferm. Dig. 2014, 106, 246–254. [PubMed]
41. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [CrossRef] [PubMed]
42. Voskens, C.J.; Goldinger, S.M.; Loquai, C.; Robert, C.; Kaehler, K.C.; Berking, C.; Bergmann, T.; Bockmeyer, C.L.; Eigentler, T.; Fluck, M., et al. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013, 8, e53745. [CrossRef] [PubMed]
43. Goekkurt, E.; Stoehlmacher, J.; Stueber, C.; Wolschke, C.; Eiermann, T.; Iacobelli, S.; Zander, A.R.; Ehninger, G.; Kröger, N. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 2007, 27, 4377–4380. [PubMed]
44. Andrade, R.J.; Robles, M.; Ulzurrun, E.; Lucena, M.I. Drug-induced liver injury: Insights from genetic studies. Pharmacogenomics 2009, 10, 1467–1487. [CrossRef] [PubMed]
45. Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe’er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41, 816–819. [CrossRef] [PubMed]
46. Lucena, M.I.; Molokhia, M.; Shen, Y.; Urban, T.J.; Aithal, G.P.; Andrade, R.J.; Day, C.P.; Ruiz-Cabello, F.; Donaldson, P.T.; Stephens, C., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338–347. [CrossRef] [PubMed]
47. Singer, J.B.; Lewitzky, S.; Leroy, E.; Yang, F.; Zhao, X.; Klickstein, L.; Wright, T.M.; Meyer, J.; Paulding, C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42, 711–714. [CrossRef] [PubMed]
48. Alfirevic, A.; Gonzalez-Galarza, F.; Bell, C.; Martinsson, K.; Platt, V.; Bretland, G.; Evely, J.; Lichtenfels, M.; Cederbrant, K.; French, N., et al. In silico analysis of HLA associations with drug-induced liver injury: Use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012, 4. [CrossRef] [PubMed]
49. Schaid, D.J.; Spraggs, C.F.; McDonnell, S.K.; Parham, L.R.; Cox, C.J.; Ejlertsen, B.; Finkelstein, D.M.; Rappold, E.; Curran, J.; Cardon, L.R., et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J. Clin. Oncol. 2014, 32, 2296–2303. [CrossRef] [PubMed]
50. Aithal, G.; Nicoletti, P.; Bjornsson, E.; Lucena, M.I.; Andrade, R.J.; Grove, J.; Stephens, C.; Hallberg, P.; Maitland-van der Zee, A.H.; Martin, J.H., et al. HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds. Hepatology 2015, 65 (Suppl. 1), 325A–326A.
51. Stephens, C.; Andrade, R.J.; Lucena, M.I. Mechanisms of drug-induced liver injury. Curr. Opin. Allergy Clin. Immunol. 2014, 14, 286–292. [CrossRef] [PubMed]
52. Chen, M.; Suzuki, A.; Borlak, J.; Andrade, R.J.; Lucena, M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 2015, 63, 503–514. [CrossRef] [PubMed]
53. Dara, L.; Liu, Z.; Kaplowitz, N. Mechanisms of Adaptation and Progression in Idiosyncratic Drug Induced Liver Injury, Clinical Implications. Liver Int. 2016, 32, 158–165. [CrossRef] [PubMed]
54. Adams, D.H.; Ju, C.; Ramaiah, S.K.; Uetrecht, J.; Jaeschke, H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 2010, 115, 307–321. [CrossRef] [PubMed]
55. Uetrecht, J.P. New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system. Chem. Res. Toxicol. 1999, 12, 387–395. [CrossRef] [PubMed]
56. Lammert, C.; Einarsson, S.; Saha, C.; Niklasson, A.; Bjornsson, E.; Chalasani, N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals. Hepatology 2008, 47, 2003–2009. [CrossRef] [PubMed]
57. Lammert, C.; Bjornsson, E.; Niklasson, A.; Chalasani, N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51, 615–620. [CrossRef] [PubMed]
58. Carrascosa, M.F.; Salcines-Caviedes, J.R.; Lucena, M.I.; Andrade, R.J. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity? J. Hepatol. 2015, 62, 751–752. [CrossRef] [PubMed]
59. Hughes, J.D.; Blagg, J.; Price, D.A.; Bailey, S.; Decrescenzo, G.A.; Devraj, R.V.; Ellsworth, E.; Fobian, Y.M.; Gibbs, M.E.; Gilles, R.W., et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18, 4872–4875. [CrossRef] [PubMed]
60. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881–890. [CrossRef] [PubMed]
61. Chen, M.; Borlak, J.; Tong, W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58, 388–396. [CrossRef] [PubMed]
62. Weng, Z.; Wang, K.; Li, H.; Shi, Q. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications. Oncotarget 2015, 6, 17031–17038. [CrossRef] [PubMed]
63. Park, B.K.; Laverty, H.; Srivastava, A.; Antoine, D.J.; Naisbitt, D.; Williams, D.P. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem. Biol. Interact. 2011, 192, 30–36. [CrossRef] [PubMed]
64. Stepan, A.F.; Walker, D.P.; Bauman, J.; Price, D.A.; Baillie, T.A.; Kalgutkar, A.S.; Aleo, M.D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 2011, 24, 1345–1410. [CrossRef] [PubMed]
65. Obach, R.S.; Kalgutkar, A.S.; Soglia, J.R.; Zhao, S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 2008, 21, 1814–1822. [CrossRef] [PubMed]
66. Bauman, J.N.; Kelly, J.M.; Tripathy, S.; Zhao, S.X.; Lam, W.W.; Kalgutkar, A.S.; Obach, R.S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 2009, 22, 332–340. [CrossRef] [PubMed]
67. Xu, J.J.; Henstock, P.V.; Dunn, M.C.; Smith, A.R.; Chabot, J.R.; de Graaf, D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105, 97–105. [CrossRef] [PubMed]
68. Leone, A.; Nie, A.; Brandon Parker, J.; Sawant, S.; Piechta, L.A.; Kelley, M.F.; Maark Kao, L.; Jim Proctor, S.; Verheyen, G.; Johnson, M.D., et al. Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol. Appl. Pharmacol. 2014, 275, 189–97. [CrossRef] [PubMed]
69. Pulkes, T.; Hanna, M.G. Human mitochondrial DNA diseases. Adv. Drug Deliv. Rev. 2001, 49, 27–43. [CrossRef]
70. Boelsterli, U.A.; Lim, P.L. Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 2007, 220, 92–107. [CrossRef] [PubMed]
71. Porceddu, M.; Buron, N.; Roussel, C.; Labbe, G.; Fromenty, B.; Borgne-Sanchez, A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol. Sci. 2012, 129, 332–345. [CrossRef] [PubMed]
72. Dykens, J.A.; Will, Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12, 777–785. [CrossRef] [PubMed]
73. Labbe, G.; Pessayre, D.; Fromenty, B. Drug-induced liver injury through mitochondrial dysfunction: Mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 2008, 22, 335–353. [CrossRef] [PubMed]
74. Chen, M.; Tung, C.W.; Shi, Q.; Guo, L.; Shi, L.; Fang, H.; Borlak, J.; Tong, W. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the “rule-of-two” model. Arch. Toxicol. 2014, 88, 1439–1449. [CrossRef] [PubMed]
75. Lucena, M.I.; García-Martín, E.; Andrade, R.J.; Martínez, C.; Stephens, C.; Ruiz, J.D.; Ulzurrun, E.; Fernández, M.C.; Romero-Gómez, M.; Castiella, A., et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 2010, 52, 303–312. [CrossRef] [PubMed]
76. Han, D.; Dara, L.; Win, S.; Than, T.A.; Yuan, L.; Abbasi, S.Q.; Liu, Z.X.; Kaplowitz, N. Regulation of drug-induced liver injury by signal transduction pathways: Critical role of mitochondria. Trends Pharmacol. Sci. 2013, 34, 243–253. [CrossRef] [PubMed]
77. Ulzurrun, E.; Stephens, C.; Crespo, E.; Ruiz-Cabello, F.; Ruiz-Nuñez, J.; Saenz-López, P.; Moreno-Herrera, I.; Robles-Diaz, M.; Hallal, M.; Moreno-Planas, J.M., et al. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int. 2013, 33, 1378–1385. [CrossRef] [PubMed]
78. Morgan, R.E.; Trauner, M.; van Staden, C.J.; Lee, P.H.; Ramachandran, B.; Eschenberg, M.; Afshari, C.A.; Qualls, C.W., Jr.; Lightfoot-Dunn, R.; Hamadeh, H.K. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 2010, 118, 485–500. [CrossRef] [PubMed]
79. Dawson, S.; Stahl, S.; Paul, N.; Barber, J.; Kenna, J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 2012, 40, 130–138. [CrossRef] [PubMed]
80. Pérez, L.M.; Milkiewicz, P.; Elias, E.; Coleman, R.; Sánchez Pozzi, E.J.; Roma, M.G. Oxidative stress induces internalization of the bile salt export pump, Bsep, and bile salt secretory failure in isolated rat hepatocyte couplets: A role for protein kinase C and prevention by protein kinase A. Toxicol. Sci. 2006, 91, 150–158. [CrossRef] [PubMed]
81. Aleo, M.D.; Luo, Y.; Swiss, R.; Bonin, P.D.; Potter, D.M.; Will, Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014, 60, 1015–1022. [CrossRef] [PubMed]
82. Geier, A.; Wagner, M.; Dietrich, C.G.; Trauner, M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 2007, 1773, 283–308. [CrossRef] [PubMed]
83. Köck, K.; Ferslew, B.C.; Netterberg, I.; Yang, K.; Urban, T.J.; Swaan, P.W.; Stewart, P.W.; Brouwer, K.L. Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 2014, 42, 665–674. [CrossRef] [PubMed]
84. Morgan, R.E.; van Staden, C.J.; Chen, Y.; Kalyanaraman, N.; Kalanzi, J.; Dunn, R.T., 2; Afshari, C.A.; Hamadeh, H.K. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 2013, 136, 216–241. [CrossRef] [PubMed]
85. Mitchell, S.J.; Hilmer, S.N. Drug-induced liver injury in older adults. Ther. Adv. Drug Saf. 2010, 1, 65–77. [CrossRef] [PubMed]
86. Felker, D.; Lynn, A.; Wang, S.; Johnson, D.E. Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. Expert Rev. Clin. Pharmacol. 2014, 7, 211–218. [CrossRef] [PubMed]
87. Fountain, F.F.; Tolley, E.; Chrisman, C.R.; Self, T.H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: A 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128, 116–123. [CrossRef] [PubMed]
88. Heubi, J.E.; Partin, J.C.; Partin, J.S.; Schubert,W.K. Reye’s syndrome: Current concepts. Hepatology 1987, 7, 155–164. [CrossRef] [PubMed]
89. De Abajo, F.J.; Montero, D.; Madurga, M.; García Rodríguez, L.A. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br. J. Clin. Pharmacol. 2004, 58, 71–80. [CrossRef] [PubMed]
90. Larrey, D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis. 2002, 22, 145–155. [CrossRef] [PubMed]
91. Fontana, R.J.; Hayashi, P.H.; Gu, J.; Reddy, K.R.; Barnhart, H.; Watkins, P.B.; Serrano, J.; Lee, W.M.; Chalasani, N.; Stolz, A., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014, 147, 96–108. [CrossRef] [PubMed]
92. Aceti, A.; Pasquazzi, C.; Zechini, B.; de Bac, C.; Group, L. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J. Acquir. Immune Defic. Syndr. 2002, 29, 41–48. [CrossRef] [PubMed]
93. Servoss, J.C.; Kitch, D.W.; Andersen, J.W.; Reisler, R.B.; Chung, R.T.; Robbins, G.K. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989–1999). J. Acquir. Immune Defic. Syndr. 2006, 43, 320–323. [CrossRef] [PubMed]
94. Sulkowski, M.S.; Thomas, D.L.; Mehta, S.H.; Chaisson, R.E.; Moore, R.D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002, 35, 182–189. [CrossRef] [PubMed]
95. Shu, C.C.; Lee, C.H.; Lee, M.C.; Wang, J.Y.; Yu, C.J.; Lee, L.N. Hepatotoxicity due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical centre. Int. J. Tuberc. Lung Dis 2013, 17, 934–939. [CrossRef] [PubMed]
96. Liu, Y.M.; Cheng, Y.J.; Li, Y.L.; Liu, C.E.; Hsu, W.H. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Lung 2014, 192, 205–210. [CrossRef] [PubMed]
97. Wang, J.Y.; Liu, C.H.; Hu, F.C.; Chang, H.C.; Liu, J.L.; Chen, J.M.; Yu, C.J.; Lee, L.N.; Kao, J.H.; Yang, P.C. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J. Infect. 2011, 62, 448–455. [CrossRef] [PubMed]
98. Lomtadze, N.; Kupreishvili, L.; Salakaia, A.; Vashakidze, S.; Sharvadze, L.; Kempker, R.R.; Magee, M.J.; del Rio, C.; Blumberg, H.M. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE 2013, 8, e83892. [CrossRef] [PubMed]
99. Ungo, J.R.; Jones, D.; Ashkin, D.; Hollender, E.S.; Bernstein, D.; Albanese, A.P.; Pitchenik, A.E. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 1998, 157, 1871–1876. [CrossRef] [PubMed]
100. Teschke, R.; Andrade, R.J. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology 2015, 148, 1271–1273. [CrossRef] [PubMed]
101. Tilling, L.; Townsend, S.; David, J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin. Drug Investig. 2006, 26, 55–62. [CrossRef] [PubMed]
102. Amital, H.; Arnson, Y.; Chodick, G.; Shalev, V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009, 48, 1107–1110. [CrossRef] [PubMed]
103. Aithal, G.P. Hepatotoxicity related to antirheumatic drugs. Nat. Rev. Rheumatol. 2011, 7, 139–150. [CrossRef] [PubMed]
104. Medina-Cáliz, I.; Garcia-Muñoz, B.; Robles Diaz, M.; Stephens, C.; González-Jiménez, A.; García-Cortés, M.; Ortega, A.; Hidalgo, R.; Fernández, M.C.; Romero-Gómez, M., et al. Risk factors for chronicity in idiosyncratic drug-induced liver injury (DILI). Hepatology 2014, 60 (Suppl. 4), 139A.
105. Lucena, M.I.; Andrade, R.J.; Vicioso, L.; González, F.J.; Pachkoria, K.; García-Muñoz, B. Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. World J. Gastroenterol. 2006, 12, 5244–5246. [PubMed]
106. Björnsson, E.; Jacobsen, E.I.; Kalaitzakis, E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56, 374–380. [CrossRef] [PubMed]
107. Aithal, G.P. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: Current role in clinical practice. Liver Int. 2015, 35, 1801–1808. [CrossRef] [PubMed]
108. Andrade, R.J. Reducing Risk of Severe Liver Injury in Patients TreatedWith Isoniazid. Clin. Gastroenterol. Hepatol. 2015, 13, 1683–1685. [CrossRef] [PubMed]